Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shanghai MicroPort Endovascular MedTech Co., Ltd. (688016.SS)
CNY93.52
+1.42 (+1.54%)
CN SHH Healthcare Medical - Devices
Address
Building 1 201318
Shanghai, CN
Shanghai, CN
CEO
Qing Zhu
Website
endovastec.com
IPO
2019-07-22
ISIN CNE100003MJ5
Description
Established in Shanghai, PRC, in 2012, Shanghai MicroPort Endovascular MedTech Co., Ltd. specializes in the creation, production, and distribution of medical technologies and products, primarily addressing aortic and peripheral diseases. The company's key offerings include TAA and AAA stent graft systems, as well as different types of balloon catheters such as inflation and PTA dilatation catheters. It operates as a subsidiary of Shanghai MicroPort Medical (Group) Co., Ltd.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY93.52
+1.42 (+1.54%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.17
Float Shares
69.97M
Free Float %
57.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.47% | +2.80% | -0.18% | +0.63% | +9.26% | +11.43% | +16.15% | -6.20% | -59.31% | -3.86% | -3.86% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
93.52
DCF (Unlevered)
167.96
+79.6%
DCF (Levered)
157.06
+67.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
15.42
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
4 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
4 / 5
High
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
★ Strong MOAT
-
Revenue growth Medical - Devices: +11.2%+12.0% ★ Q1'26: +11.5% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+14.3% Q1'26: +21.9% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+34.0% Q1'26: -5.0% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+48.4% ★ Q1'26: +48.6% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+27.7% ★ Q1'26: +28.2% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%-1.8% ★ Q1'26: -2.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.01× ★ Q1'26: 0.01× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 5 EPS Ana. |
Dec 2027 6 Rev. Ana. 6 EPS Ana. |
Dec 2028 4 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
333.73M
est: 328.52M (+1.6%)
|
470.25M
est: 458.15M (+2.6%)
|
684.63M
est: 682.45M (+0.3%)
|
896.50M
est: 906.13M (-1.1%)
|
1.19B
est: 1.35B (-12.2%)
|
1.21B
est: 1.24B (-2.7%)
|
1.35B
est: 1.55B (-12.7%)
|
1.56B
1.42B – 2.18B
+0.7% YoY
|
1.81B
1.69B – 2.16B
+16.0% YoY
|
2.11B
2.09B – 2.13B
+16.6% YoY
|
| EBITDA |
174.26M
est: 153.79M (+13.3%)
|
263.59M
est: 214.47M (+22.9%)
|
379.05M
est: 319.47M (+18.6%)
|
438.88M
est: 424.18M (+3.5%)
|
598.34M
est: 710.83M (-15.8%)
|
688.67M
est: 651.40M (+5.7%)
|
687.82M
est: 812.79M (-15.4%)
|
818.40M
745.12M – 1.14B
+0.7% YoY
|
949.61M
886.60M – 1.14B
+16.0% YoY
|
1.11B
1.10B – 1.12B
+16.6% YoY
|
| EBIT |
164.44M
est: 145.50M (+13.0%)
|
249.67M
est: 202.90M (+23.0%)
|
363.59M
est: 302.24M (+20.3%)
|
416.23M
est: 401.31M (+3.7%)
|
574.31M
est: 677.78M (-15.3%)
|
654.23M
est: 621.12M (+5.3%)
|
653.37M
est: 775.00M (-15.7%)
|
780.36M
710.48M – 1.09B
+0.7% YoY
|
905.47M
845.38M – 1.08B
+16.0% YoY
|
1.06B
1.05B – 1.06B
+16.6% YoY
|
| Net Income |
141.76M
est: 149.31M (-5.1%)
|
214.61M
est: 239.45M (-10.4%)
|
315.86M
est: 362.14M (-12.8%)
|
356.88M
est: 447.36M (-20.2%)
|
492.43M
est: 616.43M (-20.1%)
|
502.10M
est: 617.06M (-18.6%)
|
563.21M
est: 588.53M (-4.3%)
|
639.03M
612.71M – 654.36M
+8.6% YoY
|
758.53M
678.81M – 872.92M
+18.7% YoY
|
837.38M
812.06M – 899.28M
+10.4% YoY
|
| SGA |
70.50M
est: 55.55M (+26.9%)
|
76.70M
est: 77.47M (-1.0%)
|
103.81M
est: 115.40M (-10.0%)
|
150.02M
est: 153.23M (-2.1%)
|
185.19M
est: 212.48M (-12.8%)
|
250.25M
est: 194.71M (+28.5%)
|
139.02M
est: 242.95M (-42.8%)
|
244.63M
222.73M – 342.18M
+0.7% YoY
|
283.85M
265.02M – 339.27M
+16.0% YoY
|
331.05M
328.33M – 333.77M
+16.6% YoY
|
| EPS |
1.55
est: 1.21 (+28.1%)
|
2.00
est: 1.94 (+3.0%)
|
2.95
est: 2.94 (+0.5%)
|
3.33
est: 3.63 (-8.2%)
|
4.57
est: 5.32 (-14.1%)
|
4.07
est: 4.47 (-9.0%)
|
4.65
est: 5.06 (-8.1%)
|
5.23
5.06 – 5.40
+3.5% YoY
|
6.00
5.60 – 7.21
+14.6% YoY
|
6.93
6.70 – 7.42
+15.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-26 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-25 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-15 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-14 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-13 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-12 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-11 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-08 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-29 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-28 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-23 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-22 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
305.55M
OE per share TTM
2.50
Owner's Yield
2.47%
Maintenance CapEx ratio
14.03%
Maint CapEx / Avg PPE
19.5%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 18 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 455.7K | 0.06% |
| 2 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 263.0K | 0.39% |
| 3 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 36.6K | 0.26% |
| 4 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 16.2K | 0.48% |
| 5 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.81M | 0.06% |
| 6 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 109.6K | 0.28% |
| 7 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 52.4K | 0.29% |
| 8 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 2.7K | 0.44% |
| 9 | Vanguard Total International Stock ETF VXUS | 0.00% | 1.85M | 0.05% |
| 10 | Vanguard ESG International Stock ETF VSGX | 0.00% | 14.8K | 0.10% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
791.0K
Shares Outstanding
120.84M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chun Fang Li | Accounting Supervisor & Chief Financial Officer | — | female |
| Genyong Qiu | Deputy GM & Secretary of the Board of Directors | — | male |
| Hongjie Lu | Core Technical Staff | — | female |
| Ke Chen | Senior Director | — | male |
| Lantao Guo | Deputy GM & Core Technical Personnel | — | male |
| Liwen Wang | Core Technical Staff | — | female |
| Qing Zhu | GM & Director | — | male |
| Zhenyu Yuan | Deputy GM, Core Technical Personnel & Employee Representative Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688016.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
